How Do CD123, CD4, and CD56 Support BPDCN Diagnosis?

When reviewing a pathology report for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), you will likely see a list of letters and numbers like CD123, CD4, and CD56. These refer to specific proteins (markers) found on your cells. In BPDCN, the cancer cells commonly display this pattern of markers, and their presence—when evaluated alongside your clinical symptoms and cell appearance—supports your diagnosis ^[1][2].

What Do These Markers Mean?

Your immune system is made of many different types of cells, and each type has an overlapping combination of markers. Pathologists use tests to identify these markers and figure out exactly what kind of cell has become cancerous.

In BPDCN, the cancer originates from precursors to plasmacytoid dendritic cells (pDCs). A common immunophenotype (marker pattern) for BPDCN is the simultaneous presence of three surface proteins:

• CD123: The alpha chain of the interleukin-3 receptor, which is usually highly expressed on BPDCN cells ^[3]. However, it can also be found on normal pDCs and other blood cancers ^[4].
• CD4: A protein commonly associated with certain T-cells of the immune system, but not exclusive to them ^[1].
• CD56: A protein typically found on natural killer (NK) cells, but also present in other conditions ^[1].

While seeing CD123, CD4, and CD56 together is a characteristic pattern in BPDCN, the disease does have variations. In some cases, a patient’s BPDCN cells might be missing CD4 or CD56, or the intensity of the markers can vary depending on the specimen type, sample quality, and the testing method used ^[5][6][7].

Distinguishing BPDCN from Other Cancers

Having CD123, CD4, and CD56 is not enough on its own to definitively diagnose BPDCN ^[8]. Other blood cancers, such as Acute Myeloid Leukemia (AML) or certain lymphomas, can sometimes display the same surface markers ^[8][4].

To be certain, a hematopathologist interprets the whole pattern of your markers, looking for:

• Additional pDC markers: Pathologists look for other proteins (often found inside the cell or nucleus) specific to plasmacytoid dendritic cells, such as TCL1, TCF4, CD303, or CD304 ^[2][9]. The combination of these markers strongly supports a BPDCN diagnosis.
• Lineage markers from other cancers: Your report will also note the absence of markers that usually define other blood cancers, such as MPO (often seen in AML), surface or cytoplasmic CD3 (seen in T-cell lymphomas), and CD19 or CD20 (seen in B-cell lymphomas) ^[1][2]. Because marker expression can be aberrant, these negative results are interpreted as part of the larger panel, not as simple “rule-outs”.

Why CD123 is Important for Treatment

Among these markers, CD123 plays an important role because it is the target for a BPDCN therapy called tagraxofusp (Elzonris) ^[3][10].

Tagraxofusp is a targeted fusion protein that combines interleukin-3 (which naturally binds to CD123) with a truncated diphtheria toxin ^[11][12]. When the drug attaches to CD123 on the cancer cell surface, it is drawn inside, where the toxin is released to disrupt protein synthesis and destroy the cell ^[11][12].

While CD123 expression is necessary for this therapy to work, it does not guarantee that you are a candidate or that the treatment will be successful ^[13]. Treatment choice depends on many factors, including your age, overall health, organ function, and transplant plans ^[14]. Additionally, tagraxofusp can cause a serious and potentially life-threatening side effect called capillary leak syndrome, which requires close medical monitoring ^[15].

Receiving a complex pathology report can be stressful and confusing. It is completely normal to ask your care team to walk you through exactly what your results mean for your diagnosis and treatment options.